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The most widely used risk assessment tool in AF is the CHADS 2 score, which is based on risk factors identified in the early trials of warfarin in non-valvular AF. 1 The CHADS 2 acronym is easy to remember and has become a fixture of guidelines, clinical practice, and trial design. Unfortunately, its predictive ability is mediocre. The standard assessment of the discriminating ability of a prediction rule is the C-statistic, which is roughly interpretable as the probability the score will be higher in patients who sustain a stroke vs. those who do not (the interpretation varies depending on analytic perspective). A C-statistic of 0.5 indicates that the score conveys no predictive information. In contrast, the gold standard of chronic disease cardiovascular risk prediction, the Framingham score, has demonstrated C-statistics approaching 0.8. should provide further predictive information. Female sex has been found to be a risk factor in many, but not all cohorts. 5, 6 In contrast, the independent association of stroke risk with vascular disease is not well supported. In the report of Friberg et al., the presence of vascular disease raised the relative risk of stroke by only 7% [hazard ratio (HR) 1.07, 95% confidence interval (CI) 1.01 -1.14]. In a prior analysis of nearly 80 000 individuals with AF in the UK, ischaemic heart disease (the main component of 'vascular disease') was not an independent risk factor for stroke, nor was it a risk factor in the analysis of the BAFTA trial in elderly AF patients. 7, 8 A systematic review found inconclusive evidence that coronary disease was an independent risk factor for stroke. 6 Taken together, these data suggest that vascular disease contributes little to estimating stroke risk in AF.
What are the advantages of CHA 2 DS 2 -VASc? In effect, CHA 2 DS 2 -VASc expands the range of CHADS 2 ( Figure 1) . The expanded risk score does appear to improve risk stratification for the lowest risk patients. The additional risk factors included in CHA 2 DS 2 -VASc, particularly age 65 -74 years, can identify a smaller and lower risk group that has no risk factors. In those patients with a risk score of zero, the annualized stroke rate was 0.2% for CHA 2 DS 2 -VASc vs. 0.6% for CHADS 2 . It is likely that physicians and patients would be comfortable using aspirin monotherapy at either of these very low rates of stroke. However, at a point score of 1, the scoring systems diverge. Friberg et al. 4 report an annualized stroke rate of 0.6% for CHA 2 DS 2 -VASc vs. 3.0% for CHADS 2 . An expected stroke rate of 3.0% per year seems too high for antiplatelet therapy. Recent ESC guidelines state that oral anticoagulation is 'preferred' in patients with ≥1 CHA 2 DS 2 -VASc risk factors. 1 In the Swedish registry, this approach results in recommending anticoagulation to 94% of the cohort (including all women). While CHA 2 DS 2 -VASc can identify a small percentage of patients with very low risk of stroke, it ends up characterizing nearly all the rest as high risk. Certainly, most CHA 2 DS 2 -VASc ≥2 patients merit anticoagulation, particularly given the lower risk of intracranial haemorrhage with novel oral anticoagulants. However, the annual stroke rate of 0.6% in patients with a CHA 2 DS 2 -VASc ¼ 1 seems too low to justify anticoagulation. It is important to remember that patients who are CHADS 2 ¼ 0 and CHA 2 DS 2 -VASc ¼ 1 have largely been excluded from the major trials of novel oral anticoagulation. Additionally, Friberg et al. only included hospitalbased patients, probably biasing towards higher stroke rates. 4 Ultimately, an aggressive approach in low risk patients may be warranted, but we should appreciate that this strategy is not well supported by trial results. We do need stroke risk prediction tools that are clearly better than the CHADS 2 score. Until they appear, clinicians should consider additional risk factors for patients where the anticoagulation decision is particularly troublesome. Such risk factors would include female gender, older age, and presence of renal dysfunction. 9 What about bleeding scores? Many guidelines have cautioned against use of anticoagulants in patients at increased risk of bleeding, but failed to specify how to estimate bleeding risk. There are now several bleeding scores developed specifically for patients with AF. 4, 10 One of these scores, HAS-BLED, was incorporated into the recent ESC guidelines. Friberg et al. compared HAS-BLED with the HEMORR 2 HAGES score and concluded that they have 'similar predictive value', although the point estimate of the C-statistic was higher for HEMORR 2 HAGES (0.63 vs. 0.61). The comparison was hampered by the absence of several risk factors included in the original scores. The authors argue that HAS-BLED has the advantage of 'simplicity', but HAS-BLED strikes us as fairly complicated and unlikely to serve as a 'simple' bedside tool. It has seven categories of risk factors, a pair of subcategories (e.g. A ¼ 'abnormal' renal and liver function), and multiple risk factors whose definitions are not intuitive. Both the HAS-BLED and HEMORR 2 HAGES scores would be difficult to use without formal scoring aids. While it makes sense to incorporate bleeding risk scores into the anticoagulation decision, the process is not straightforward. First, bleeding risk scores need to be tested in multiple cohorts; their current track record is quite limited. Secondly, balancing stroke and bleeding risk is complex. The most common type of major bleeding is extracranial, such as gastrointestinal haemorrhage, which, on average, has much less clinical impact than ischaemic stroke. In contrast, intracranial haemorrhage is often fatal, yet bleeding scores lump these events together. As a result, withholding anticoagulation based simply on a bleeding risk score is a premature and potentially harmful recommendation. For example, if we take a hypothetical patient with a CHADS 2 score of 2 and a HASBLED score of 5, the estimated untreated annualized risk of Figure 1 The rates of ischaemic stroke per 100 patient years in the Swedish Registry according to both the CHADS 2 and CHA 2 DS 2 -VASc scores. Immediately below the x-axis, the range of low, intermediate, and high risk scores are illustrated, as well as the frequency of each score in the overall registry population (% of cohort).
Editorial ischaemic stroke in the Swedish register is 4.7% and the absolute increase in the intracranial bleeding rate with oral anticoagulation is 0.4% (1.2-1.6%). It is hard to imagine this patient would benefit from avoidance of oral anticoagulation. Balancing stroke and bleed risk scores is even more difficult because bleeding risk and stroke risk are highly correlated such that those patients who are most likely to bleed often are also most likely to have a thrombo-embolic stroke. 11 Simply avoiding anticoagulation in AF patients at high risk for bleeding could result in preventable strokes and increased mortality. Ultimately, rational use of stroke prophylaxis should hinge on appropriately defined net clinical benefit. 12 We need better prediction rules across the risk spectrum. The ultimate goal is to identify the restricted (but significant) number of AF patients who will have a stroke and limit anticoagulation to these patients. This very challenging goal will certainly not be approached with current models. Moving forward, application of risk models should be anchored in the prevention of ischaemic stroke, avoidance of devastating haemorrhage, particularly intracranial haemorrhage, and improved survival.
